Expertise in
11
conditions

Dr. Meaghan E. Tenney

Obstetrics and Gynecology
University Gynecologic Oncology - Cumming
1100 Northside Forsyth Dr Ste 420, 
Cumming, GA 
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
University Gynecologic Oncology - Cumming
1100 Northside Forsyth Dr Ste 420, 
Cumming, GA 

Overview

Meaghan Tenney is an Obstetrics and Gynecologist practicing medicine in Cumming, Georgia.

Dr. Tenney is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Sertoli-Leydig Cell Tumor, Ovarian Carcinosarcoma, Hysterectomy, and Endoscopy.

She is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 14 clinical trials. Dr. Tenney is currently accepting new patients.

Specialties

Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in OK

Hospital Affiliations

Northside Hospital Forsyth
Northside Hospital Cherokee
Northside Hospital

Languages Spoken

English
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

University Gynecologic Oncology - Cumming
1100 Northside Forsyth Dr Ste 420, Cumming, GA 30041
Other Locations
University Gynecologic Oncology - Atlanta
960 Johnson Ferry Rd Ste 130, Atlanta, GA 30342

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS
Enrollment Status: Terminated
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 2
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: December 23, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole
Study Phase: Phase 2
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 3
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Enrollment Status: Completed
Publish Date: July 25, 2023
Intervention Type: Drug
Study Drug: Tisotumab Vedotin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

17 Total Publications

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2025
Similar Doctors
Expertise in
3
conditions
Dr. Charlotte D. Owens
Obstetrics and Gynecology
Expertise in
3
conditions
Dr. Charlotte D. Owens
Obstetrics and Gynecology
Referral may be required

Grady Memorial Hospital Corporation

80 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (35.2 miles away)
404-616-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Charlotte Owens is an Obstetrics and Gynecologist practicing medicine in Atlanta, Georgia. Dr. Owens is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Menorrhagia, Uterine Fibroids, Adenomyosis, and Amenorrhea. Dr. Owens is currently accepting new patients.

Expertise in
11
conditions
Dr. Gerald A. Feuer
Obstetrics and Gynecology
Expertise in
11
conditions
Dr. Gerald A. Feuer
Obstetrics and Gynecology
Referral may be required

Atlanta Gynecologic Oncology-Marietta

780 Canton Rd NE Ste 320, 
Marietta, GA 
 (31.7 miles away)
404-459-1900
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Gerald Feuer is an Obstetrics and Gynecologist practicing medicine in Marietta, Georgia. Dr. Feuer is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hysterectomy. Dr. Feuer is currently accepting new patients.

Expertise in
13
conditions
Dr. Michelle A. Glasgow
Obstetrics and Gynecology
Expertise in
13
conditions
Dr. Michelle A. Glasgow
Obstetrics and Gynecology
Referral may be required

Atlanta Gynecologic Oncology-Canton

470 Northside Cherokee Blvd Ste 475, 
Canton, GA 
 (17.1 miles away)
770-721-9400
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Michelle Glasgow is an Obstetrics and Gynecologist practicing medicine in Canton, Georgia. Dr. Glasgow is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Endometrial Cancer, Bladder Reconstruction, and Oophorectomy. Dr. Glasgow is currently accepting new patients.

Frequently Asked Questions about Dr. Meaghan E. Tenney

How do I make an appointment with Dr. Meaghan E. Tenney?

You can book an appointment with Dr. Meaghan E. Tenney by calling their office at 770-292-3100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Meaghan E. Tenney a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Meaghan E. Tenney is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Meaghan E. Tenney specialize in?

While Dr. Meaghan E. Tenney is a Obstetrics and Gynecology, they have specific expertise in Ovarian Cancer, Sertoli-Leydig Cell Tumor, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Obstetrics and Gynecology.

Does Dr. Meaghan E. Tenney participate in research or clinical trials?

Yes. Dr. Meaghan E. Tenney has published 17 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Meaghan E. Tenney's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Meaghan E. Tenney accept my insurance?

Dr. Meaghan E. Tenney accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 770-292-3100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tenney's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile